Sharemaestro company-news research for AstraZeneca PLC (AZN), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NYSE
United States
Provisional evidence
Company news sentiment
AZN news sentiment
AstraZeneca PLC
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score56Neutral is 50
Early balanced news score
36/100 evidence confidence
100% direct company focus
20 current stories across 10 publishers
Current company news
Early balanced news score
20 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone63/100
→
Published 30-day score56/100
Latest source headline
How AstraZeneca’s $400bn deal unravelled
finance.yahoo.com · 12 Aug 2026 04:00
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
20 current stories are mapped specifically to AZN.
The score uses 10 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.714.
56/100
News scoreEarly balanced news score
36/100
Confidencethin evidence
100%/100
Company news20 company stories
84/100
Story agreement16/100 difference
News history
Daily score and story count over 30 days
15 Jul30 Jul13 Aug
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence14
0.714 after freshness weightingSource breadth100
10 independent publishersCompany relevance100
share tied directly to this companyFreshness50
recency-weighted evidenceAgreement84
how closely stories agreePublisher mix42
less reliance on one publisherPrice and news history
News score and weekly price over 26 weeks
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
07 Aug 202653USD 161.42-4.2%
31 Jul 202654USD 168.52+0.2%
24 Jul 202654USD 168.15+0.2%
17 Jul 202649USD 167.79-1.6%
10 Jul 202650USD 170.48-12.1%
03 Jul 202650USD 193.87+2.9%
26 Jun 202650USD 188.41+7.7%
Provisional evidence
News subjects
What is shaping the score
Market update559 stories · 45%
Earnings734 stories · 20%
Deals and strategy434 stories · 20%
Regulatory and legal672 stories · 10%
Analyst action761 stories · 5%
Source mix
Where the evidence comes from
finance.yahoo.com665 stories · 25%
Market source504 stories · 20%
GuruFocus672 stories · 10%
GuruFocus.com502 stories · 10%
Seeking Alpha502 stories · 10%
The Wall Street Journal671 stories · 5%
MT Newswires571 stories · 5%
Recurring subjects
Subjects appearing most often
Oncology3ONCOLOGY3PHARMA2Clinical Trials2CLINICAL-TRIALS2PATENT-EXPIRY1PARTNERSHIP1M-A1M A1Earnings Per Share1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
20 Jun50 neutral13 Aug 23:47
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 13 Aug 23:47 | 59 | -1 | 45/100 (-1) | 37 (+1) | Measured |
| 12 Aug 23:59 | 60 | +0 | 46/100 (-2) | 36 (+2) | Measured |
| 11 Aug 23:59 | 60 | +0 | 48/100 (+8) | 34 (+6) | Measured |
| 10 Aug 23:59 | 60 | +3 | 40/100 (+1) | 28 (+2) | Measured |
| 09 Aug 23:59 | 57 | +4 | 39/100 (+5) | 26 (+1) | Measured |
| 08 Aug 23:59 | 53 | +0 | 34/100 (+3) | 25 (+1) | Provisional |
| 07 Aug 23:59 | 53 | +1 | 31/100 (+2) | 24 (+1) | Provisional |
| 06 Aug 23:59 | 52 | +0 | 29/100 (-3) | 23 (-3) | Provisional |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#176Tone
finance.yahoo.comDirect company coverageStored article
How AstraZeneca’s $400bn deal unravelled
One Broadway deal to start: Hollywood mogul Ari Emanuel has struck a roughly £4.5bn deal to buy the theatre group behind West End venues including the Lyceum and the Savoy in a major bet that strong demand for live events is here to stay. In today's newsletter: AstraZeneca's Silver Upgrade to read this Financial Times article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now
- Published
- 12 Aug 2026 04:00
- News subject
- Analyst action
- Why this score
- Operating growth
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Medium · 15.4% · 1.8d old
- Duplicates
- 5 consolidated
#240Tone
finance.yahoo.comDirect company coverageStored article
AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn’t Buy This Merger Talk
AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock's biggest one-day drop since 2020, after reports that it held merger talks with U.S. rival Bristol-Myers Squibb Company (NYSE:BMY). A combined company would be worth close to $400 billion, the fourth-largest drugmaker in the world by market value. Neither firm confirmed the talks, and people familiar with the matter told Reuters a deal may never materialize. Why Investors Can't Figure Out the Logic Bristol Myers shares actually rose as much as 6% on the news before dropping back down a bit, a very different reacti
M AM-AONCOLOGYOncologyPATENT-EXPIRYPHARMA
- Published
- 11 Aug 2026 19:34
- News subject
- Deals and strategy
- Why this score
- Negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Medium · 14.8% · 2.1d old
- Duplicates
- 5 consolidated
#362Tone
finance.yahoo.comDirect company coverageStored article
Hedge Funds are Bullish on AstraZeneca PLC (AZN)
AstraZeneca PLC (NYSE:AZN) topped second-quarter profit expectations, with core earnings per share of $2.63 versus the $2.48 analysts expected. The firm reiterated its target of $80 billion in annual revenue by 2030. However, the quarter also brought fresh pipeline trouble: its rare disease drug Ultomiris missed its main goal in a late-stage trial for a rare blood vessel complication in adults, the latest in a string of setbacks that also includes an earlier heart drug trial failure and a breast cancer drug application that U.S. regulators rejected. Why One Trial Miss Shook Confidence in the W
EARNINGSEARNINGS PER SHAREEarningsEarnings Per ShareONCOLOGYOncology
- Published
- 11 Aug 2026 14:04
- News subject
- Earnings
- Why this score
- Beat expectations
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Medium · 15.6% · 2.4d old
- Duplicates
- 5 consolidated
#481Tone
finance.yahoo.comDirect company coverageStored article
Can AstraZeneca (AZN) Reach Its $80 Billion Revenue Goal Despite Clinical Setbacks?
It was reported on July 27 that AstraZeneca PLC (NASDAQ:AZN) shares outperformed in European trading after the company reported second-quarter earnings that beat Wall Street expectations and reiterated its full-year 2026 guidance. Core earnings per share (EPS) jumped 18% on a constant exchange rate (FXN) basis year-over-year to $2.63, comfortably ahead of the $2.48 analyst consensus. Total revenue reached $15.38 billion, up 5% at constant exchange rates, driven primarily by sustained momentum in its Oncology and Rare Disease units. Management reconfirmed its full-year 2026 outlook of mid-to-hi
BALANCE SHEETBalance SheetCLINICAL-TRIALSClinical TrialsDIVIDENDSDividends
- Published
- 10 Aug 2026 23:44
- News subject
- Earnings
- Why this score
- Beat expectations, Positive market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- High · 23.9% · 3.0d old
- Duplicates
- 5 consolidated
#550Tone
finance.yahoo.comDirect company coverageStored article
AstraZeneca (LSE:AZN) Signs Two Cancer Diagnostics Deals To Widen Patient Access
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. SOPHiA GENETICS and AstraZeneca (LSE:AZN) have entered a global partnership to develop and launch two decentralized companion diagnostics in precision oncology. The multi-year collaboration focuses on clinical trial assays that support development and commercialization of AstraZeneca's oncology therapies. The partners aim to expand access to personalized cancer treatments by enabling decentralized testing across a wider range of clinical settings. For readers tracking how data driven too
CLINICAL-TRIALSClinical TrialsONCOLOGYOncologyPARTNERSHIPPHARMA
- Published
- 08 Aug 2026 15:12
- News subject
- Deals and strategy
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 5.7% · 5.3d old
- Duplicates
- 5 consolidated
#657Tone
MT NewswiresDirect company coverageScored from headlineSource lookup
AstraZeneca, Jaguar Land Rover Gain Access to UK's Fast-Track Visa
- Published
- 06 Aug 2026 02:17
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 0.7% · 7.9d old
- Duplicates
- 3 consolidated
#740Tone
GuruFocus.comDirect company coverageScored from headlineSource lookup
AstraZeneca Stock Plunges 7.7% on Reported $400 Billion Merger Talks
- Published
- 03 Aug 2026 21:07
- News subject
- Deals and strategy
- Why this score
- Negative market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 6.8% · 10.1d old
- Duplicates
- 3 consolidated
#850Tone
Seeking AlphaDirect company coverageScored from headlineSource lookup
AstraZeneca, Bristol Myers held merger talks, Financial Times reports (AZN:NYSE)
- Published
- 02 Aug 2026 20:09
- News subject
- Deals and strategy
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 4% · 11.1d old
- Duplicates
- 3 consolidated
#950Tone
Seeking AlphaDirect company coverageScored from headlineSource lookup
AstraZeneca and Daiichi win EU label expansion for Datroway in breast cancer
- Published
- 02 Aug 2026 13:28
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 0.2% · 11.4d old
- Duplicates
- 3 consolidated
#1050Tone
Market sourceDirect company coverageScored from headlineSource lookup
AstraZeneca PLC (AZN) Stock Forecasts
- Published
- 28 Jul 2026 07:47
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 16.6d old
- Duplicates
- 1 consolidated
#1150Tone
Market sourceDirect company coverageScored from headlineSource lookup
AstraZeneca PLC (AZN) Stock Forecasts
- Published
- 28 Jul 2026 07:47
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 16.6d old
- Duplicates
- 1 consolidated
#1250Tone
Market sourceDirect company coverageScored from headlineSource lookup
AstraZeneca PLC (AZN) Stock Forecasts
- Published
- 28 Jul 2026 07:47
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 16.6d old
- Duplicates
- 1 consolidated
#1375Tone
GuruFocus.comDirect company coverageScored from headlineSource lookup
AstraZeneca's $2.63 Earnings Beat Supports $80 Billion Revenue Target
- Published
- 27 Jul 2026 21:00
- News subject
- Earnings
- Why this score
- Beat expectations
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 2.8% · 17.1d old
- Duplicates
- 3 consolidated
#1450Tone
Ad-hoc-news.deDirect company coverageScored from headlineSource lookup
AstraZeneca stock trades steadily as oncology and cardiovascular growth underpin recent earnings
- Published
- 27 Jul 2026 14:22
- News subject
- Earnings
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 1% · 17.4d old
- Duplicates
- 3 consolidated
#1567Tone
GuruFocusDirect company coverageScored from headlineSource lookup
AstraZeneca's (AZN) Etcamah Secures EU Approval for Breast Cance
- Published
- 23 Jul 2026 13:36
- News subject
- Regulatory and legal
- Why this score
- Contract or approval won
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 3.4% · 21.4d old
- Duplicates
- 3 consolidated
#1667Tone
The Wall Street JournalDirect company coverageScored from headlineSource lookup
AstraZeneca Wins EU Approval for Breast-Cancer Drug as U.S. Review Continues
- Published
- 23 Jul 2026 10:30
- News subject
- Regulatory and legal
- Why this score
- Contract or approval won
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · 5.6% · 21.5d old
- Duplicates
- 3 consolidated
#1750Tone
GuruFocusDirect company coverageScored from headlineSource lookup
AstraZeneca (AZN) Faces Changes Amid New U.S. Drug Tariff Regula
- Published
- 22 Jul 2026 02:30
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 22.8d old
- Duplicates
- 3 consolidated
#1850Tone
CryptoSlateDirect company coverageScored from headlineSource lookup
AstraZeneca Tokenized Stock price today, AZNX to USD chart, marketcap and volume
- Published
- 17 Jul 2026 10:14
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 27.5d old
- Duplicates
- 3 consolidated
#1950Tone
Market sourceDirect company coverageScored from headlineSource lookup
AstraZeneca (LSE:AZN) Stock Could Trade At A 46% Discount After Wainua Setback
- Published
- 15 Jul 2026 11:11
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 29.5d old
- Duplicates
- 3 consolidated
#2050Tone
Pharmaceutical TechnologyDirect company coverageScored from headlineSource lookup
AstraZeneca pays up to $1.5bn to license Dizal Pharma’s lung cancer drug
- Published
- 15 Jul 2026 04:40
- News subject
- Market update
- Why this score
- No clear positive or negative phrase
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Weighted influence
- Low · <0.1% · 29.8d old
- Duplicates
- 3 consolidated
Earlier company news
AZN news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 24 older AZN headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to AZN, but the headline and available text are not mainly about AstraZeneca PLC. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of AZN sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.